TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02407223

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1: Placebo
Description: Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
Study: NCT01920854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01775150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education
Description: Health education via text messaging
Study: NCT01304433

Intervention type: DRUG
Intervention: Venofundin 6% / Tetraspan 6%
Description: Venofundin 6% / Tetraspan 6%
Study: NCT00939666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wait&see or TEM with intensive follow-up
Description: Wait\&see or TEM with intensive follow-up
Study: NCT01666964

Intervention type: OTHER
Intervention: Blast Traumatic Brain Injury
Description: Exposure during combat to blast-wave mediated Traumatic Brain Injury

Intervention type: OTHER
Intervention: Blast Traumatic Brain Injury
Description: Exposure during combat to blast-wave mediated Traumatic Brain Injury
Study: NCT02231801

Intervention type: BEHAVIORAL
Intervention: Mother-Infant Dyad
Description: Skin-to-skin holding of preterm infants by their mothers
Study: NCT02407223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Ustekinumab 45 mg
Description: Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: Ustekinumab 90 mg
Description: Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
Study: NCT02602535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
Study: NCT00803751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope
Description: will use the Truview laryngoscope instead of the traditional Macintosh laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Intubation using the traditional Macintosh laryngoscope
Study: NCT02463110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.

Intervention type: DRUG
Group type: OTHER
Intervention: No treatment
Study: NCT04019899

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: * 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: study group
Description: * 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.
Study: NCT02507323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: A platelet aggregation inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: a thienopyridine class inhibitor of platelet activation and aggregation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00597402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (XRT)
Description: Treatment with standard XRT (radiation) for 6.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
Study: NCT05342558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate/Vilanterol 100/25 mcgs
Description: Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate/Vilanterol 100/25 mcgs
Description: Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umeclidinium/Vilanterol 62.5/25 mcgs
Description: Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umeclidinium/Vilanterol 62.5/25 mcgs
Description: Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks
Study: NCT05113511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510
Description: Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.
Study: NCT02986711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Text Messages
Description: Motivational text messages in addition to survey questions about smoking status

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Only survey questions about smoking status
Study: NCT00858026

Intervention type: OTHER
Group type: OTHER
Intervention: Breastmilk
Description: Exclusively breastfed babies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard milk
Description: Weaning babies fed with the standard formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented milk
Description: Weaning babies fed with the fermented formula
Study: NCT01454791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac sodium topical gel
Description: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diclofenac sodium topical gel
Description: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: a placebo gel is applied 1-4 times per day for two weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo gel is applied 1-4 times per day for two weeks.
Study: NCT01467505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressant Regimen
Description: Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressant Regimen
Description: Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
Study: NCT02719171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab administered by SC injection
Study: NCT00227721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
Study: NCT02463110

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03732404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preoperative carbohydrate loading
Description: Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive plain water with the same volume and timing of treatment.
Study: NCT00227721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride
Description: 800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
Study: NCT02264158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan low
Study: NCT03745261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (Ventolin®)
Description: According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
Study: NCT02264158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan low

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacidipine high

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacidipine low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine low

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03826121

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sesame Oil Cake Extract
Description: Sesame Oil Cake Extract 1.5 g/day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 12 weeks.
Study: NCT03476148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Rehabilitation using Interactive device
Description: Rehabilitation is performed using interactive motion tracking augmented reality device. 6 exercises are included in one-day rehabilitation program. Each exercise is recorded in aspect of compliance, completion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Rehabilitation
Description: Patients are given the exercises in the setting of inpatient rehabilitation
Study: NCT00905463

Intervention type: PROCEDURE
Intervention: Lung transplantation
Description: Lung transplantation
Study: NCT01029184

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: commercialized complete cereals
Description: complete cereals suitable for the weaning period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: commercialized complete cereals with additional ingredient
Description: complete cereals suitable for weaning period
Study: NCT03049917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Conditional cash transfer upon HIV testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Conditional cash transfer upon HIV testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Conditional cash transfer upon HIV testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Conditional cash transfer upon HIV testing
Study: NCT02620969

Intervention type: OTHER
Intervention: Blood and dialysate sampling
Description: Blood and dialysate sampling
Study: NCT01550536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance and aerobic exercise
Description: Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
Study: NCT01425502

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DQIP Intervention
Description: The DQIP intervention comprises of:~* Educational outreach~* Information technology application~* Financial incentives
Study: NCT02534545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doctormate® (200mmHg)
Description: Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Doctormate® (60mmHg)
Description: Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
Study: NCT03947177

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GMIT
Description: Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMIT+
Description: Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices. Parents and/or guardians will virtually participate in parent-only support group sessions.
Study: NCT03923257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-tyr3-OCTREOTATE
Description: This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptide Receptor Radiotherapy (PRRT)
Description: PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.
Study: NCT01212861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprachoroidal Dissection Instrument (SDI)
Description: The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
Study: NCT03685955

Intervention type: BIOLOGICAL
Intervention: Amniotic membranes
Description: Amniotic membranes will be employed during participant's genitourinary reconstruction
Study: NCT03745261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide (Spiriva®)
Description: Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide (Spiriva®)
Description: Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol / fluticasone (Seretide®)
Description: Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol / fluticasone (Seretide®)
Description: Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YCC capsule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
Study: NCT01446627

Intervention type: OTHER
Intervention: There is no intervention for this study
Description: None, no intervention made.

Intervention type: OTHER
Intervention: There is no intervention for this study
Description: None, no intervention made.
Study: NCT03745261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL capsule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bailing(BL) capsule (Bailing®, Huadong Medicine Co.,Ltd), 1 g each time, three times a day
Study: NCT04360343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Film-coated tablet
Description: uncoated tablet
Study: NCT01860287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2 MG Sublingual Tablet
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)
Study: NCT04360343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Film-coated tablet
Description: uncoated tablet
Study: NCT01860287

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.4 MG Sublingual Tablet
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)